Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Chemotherapy for Relapsed Germ Cell Tumors
NCT06418789Phase 2Recruiting
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Mar 2024
- Primary completion
- Mar 2029
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, ifosfamide, carboplatin and etoposide in germ cell tumor (GCT), sponsored by N.N. Petrov National Medical Research Center of Oncology. Primary endpoint: Progression Free Survival at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injectionifosfamidecarboplatinetoposide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT06418789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418789.